From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Predicting Survival in MM With Renal Impairment and Light Chain Cast Nephropathy

The quality of renal response to therapy was associated with survival in patients with multiple myeloma (MM) with renal impairment and light chain cast...
WIB_icon

BTKi Improves Disease Control in CLL After Progression on Venetoclax

Treatment with a Bruton tyrosine kinase inhibitor (BTKi) showed efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed on venetoclax, according to...
WIB_icon

Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?

Compared with the widely used International Prognostic Index (IPI) and revised IPI (R-IPI), the most recent National Comprehensive Cancer Network IPI (NCCN-IPI) better predicts...
WIB_icon

Ruxolitinib Improves Outcomes in Patients With Steroid-Refractory Graft-Versus-Host Disease

Patients with steroid-refractory acute graft-versus-host disease (GVHD) following hematopoietic cell transplant (HCT) experienced durable clinical responses by 28 days and had promising overall survival...

Tisagenlecleucel Improves Patient-Reported Quality of Life in Relapsed/Refractory DLBCL

Treatment with tisagenlecleucel was associated with clinically meaningful improvements in health-related quality of life (QoL) over 18 months in patients with diffuse large B-cell...
WIB_icon

Daratumumab Monotherapy Produces Rapid, Deep Hematologic Responses in Light Chain Amyloidosis

In a study of previously treated patients with systemic light chain amyloidosis (AL), nearly half of patients treated with intravenous (IV) daratumumab experienced at...
WIB_icon

Temozolomide Demonstrates High Response in Older Patients With Primary Vitreoretinal Lymphoma

Temozolomide demonstrated a high overall response rate in a study of patients with primary vitreoretinal lymphoma (PVRL) who were either considered ineligible for intensive...
WIB_icon

Twice-Daily Low-Dose Aspirin Improves Antiplatelet Response in Essential Thrombocythemia

Once-daily aspirin 75 to 100 mg is the current recommended antithrombotic regimen for patients with essential thrombocythemia (ET), but once-daily aspirin may not be...

High Bleeding Events in SCD Warrant Consideration of In-Hospital Ulcer Prophylaxis

By the time they reach age 40, 21% of patients with sickle cell disease (SCD) will have experienced a bleeding event, with most events...

Men Have More Published Research Than Women, Regardless of Caregiving Responsibilities

Previous research has shown that hematologists who participated in the American Society of Hematology’s (ASH’s) Clinical Research Training Institute (CRTI) experienced greater levels of...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title